Skip to main content
INVION LIMITED logo

INVION LIMITED — Investor Relations & Filings

Ticker · IVX ISIN · AU000000IVX4 LEI · 529900JY0HVEQEMSSJ32 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2012-12-16 Regulatory Filings
Country AU Australia
Listing ASX IVX

About INVION LIMITED

https://inviongroup.com

Invion Limited is a life sciences company dedicated to the development and commercialization of Photosoft technology, a next-generation Photodynamic Therapy (PDT). The company focuses on utilizing this light-activated treatment platform to target various forms of cancer and infectious diseases. Photosoft technology is derived from natural chlorophyll and is designed to selectively destroy malignant cells while minimizing damage to healthy tissue. Invion's research and development efforts are primarily directed toward oncology applications, including the treatment of skin, lung, and ovarian cancers, as well as addressing global health challenges through the treatment of viral and bacterial infections. The company aims to provide non-invasive or minimally invasive therapeutic alternatives that offer improved patient outcomes and reduced side effects compared to conventional treatment modalities.

Recent filings

Filing Released Lang Actions
Successful pre-IND meeting for INV103 (Cpn10) 2 pages 272.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX media announcement dated 17 December 2012 from Invion Limited. It reports on a successful pre-IND meeting with the FDA regarding the clinical development of a drug candidate INV103 (Cpn10) for lupus treatment. The content focuses on regulatory interaction, clinical development plans, and company statements about the drug and its development strategy. There are no financial statements, earnings data, or detailed financial analysis. The document is a public announcement about a regulatory and clinical development milestone rather than a financial report or detailed investor presentation. It does not fit into categories like Annual Report, Earnings Release, or Investor Presentation. It is a regulatory announcement about clinical development progress, which aligns best with Regulatory Filings (RNS) as a general category for regulatory and compliance-related announcements that do not fit other specific categories. The document length is under 5,000 characters, consistent with an announcement rather than a full report.
2012-12-16 English
S708A Issue of share options without disclosure 1 p
Share Issue/Capital Change Classification · 95% confidence The document is an ASX announcement dated 12 November 2012 regarding the issuance of 29,125,000 share options by Invion Limited without disclosure under section 708A of the Corporations Act 2001. It is a formal notice about a capital raising event without disclosure requirements. The document references an Appendix 3B dated 9 November 2012, which is typically related to share issue notifications. The content is a regulatory announcement about share options issuance, not a full financial report or detailed capital structure update. Given the nature of the announcement about share options issuance and compliance with disclosure laws, this fits best under the category of Share Issue/Capital Change (SHA). The document is short and does not contain financial statements or detailed analysis, so it is not an Annual Report or Interim Report. It is not a report publication announcement or a regulatory filing fallback because it provides substantive information about the share options issuance itself.
2012-11-11 English
Appendix 3B 8 pages 377.0KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B' and is an announcement related to the issue of new securities, specifically options and shares, by Invion Limited. It includes details such as the number of securities issued, exercise prices, expiry dates, and the purpose of the issue (e.g., options issued to directors and staff). The document also contains information about the quotation of these securities on the ASX (Australian Securities Exchange) and includes warranties and indemnities related to the quotation process. This type of document is a formal announcement of a capital raising or share issue event, consistent with the 'Capital/Financing Update' category. It is not a full financial report, audit report, or earnings release, nor is it a regulatory filing or proxy statement. The document length and detail confirm it is not merely a brief announcement but a substantive update on capital changes.
2012-11-08 English
Change of Director's Interest Notice 3 pages 220.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities held by a director, including the number of shares and options acquired, dates of changes, and nature of the transactions. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It does not contain financial performance data, management discussion, or other report types. The document length is 3815 characters, which is consistent with a detailed director's dealing notice. Therefore, the appropriate classification is Director's Dealing (DIRS).
2012-11-08 English
Change of Director's Interest Notice 3 pages 220.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in relevant interests in securities, including the number of shares and options acquired, dates, and nature of the change. This is a formal notification of a director's personal share transactions. The document is not a financial report, earnings release, or management discussion, but a regulatory disclosure of insider trading activity by a director. Therefore, it fits the category of Director's Dealing (DIRS). The document length is 3861 characters, consistent with a detailed insider transaction notice rather than a full report or announcement of a report.
2012-11-08 English
Change of Director's Interest Notice 3 pages 220.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including number of shares and options acquired, dates, and nature of the change. This is a report of personal share transactions by a company director, which fits the definition of Director's Dealing filings. The document is not an annual report, earnings release, or any other financial report but specifically a notice of director's interest changes.
2012-11-08 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.